Back

The COMPASS study... Vascular protection with rivaroxaban in patients with CAD or PAD.

29 August 2017 (13:15 - 13:40)
Organised by:
Congress Presentation Part of: Exploring vascular protection in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) through the potential of factor Xa inhibition... The COMPASS study Thrombosis and coagulation Open Access ESC Congress 2017

About the speakers

Photo
Doctor Stuart J Connolly

McMaster University, Hamilton (Canada)

Photo
Doctor John William Eikelboom

McMaster University, Hamilton (Canada)

3 More presentations in this session

Presentation thumbnail
Opening remarks - Exploring vascular protection in patients with CAD or PAD through the potential of factor Xa inhibition... The COMPASS study.
Doctor S. Yusuf (Hamilton, CA)
Slides Video
Presentation thumbnail
Which patients with CAD or PAD are at the highest risk of cardiovascular events... What do the registries teach us.
Professor P. Steg (Paris, FR) Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Closing remarks - Exploring vascular protection in patients with CAD or PAD through the potential of factor Xa inhibition... The COMPASS study.
Doctor S. Connolly (Hamilton, CA)
Slides

Access the full session

Session thumbnail
Exploring vascular protection in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) through the potential of factor Xa inhibition... The COMPASS study

The Event

Event poster

ESC Congress 2017

29 August 2017 13:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources